YOLFTbeta
Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

XENE · NASDAQ · Healthcare / Biotechnology

40.48USD-0.52 (-1.26%)

Price History

Full chart

Market Stats

Previous Close41.00
Open40.89
Day Range39.84 – 41.20
52-Week Range36.07 – 72.66
Volume580.75K
Market Cap3.61B
P/E (TTM)0.00
Forward P/E0.00
EPS-4.81
Dividend Yield0.00%
Beta0.62
50-Day Avg58.11
200-Day Avg53.18

About

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ian C. Mortimer C.M.A., CPA, M.B.A.
  • Employees358
  • Headquarters200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8, USA
  • Websitehttps://www.xenon-pharma.com

Leadership

  • Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.President, CEO & Director · b. 1976
  • Mr. Thomas Patrick Kelly J.D.Chief Financial Officer · b. 1971
  • Ms. Andrea DiFabio J.D.Chief Legal Officer & Corporate Secretary · b. 1968
  • Dr. Christopher John Kenney M.D.Chief Medical Officer · b. 1971
  • Mr. Darren S. Cline M.B.A.Chief Commercial Officer · b. 1964
  • Dr. Matthew D. Ronsheim Ph.D.Chief Operating Officer · b. 1972
  • Ms. Shelley McCloskey B.A.Executive Vice President of Human Resources · b. 1960
  • Dr. Robin P. Sherrington Ph.D.Executive Vice President of Strategy & Innovation · b. 1961
  • Dr. James R. Empfield Ph.D.Executive Vice President of Drug Discovery · b. 1961
  • Ms. Colleen AlabisoSenior Vice President of Corporate Affairs

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.92M14.31M27.36M28.37M15.58M1.80M311.00K06.83M32.17M18.44M9.43M007.50M
Growth (%)-+106.82%+91.19%+3.71%-45.09%-88.43%-82.75%-100.00%-+371.02%-42.68%-48.83%-100.00%--
Cost of Revenue-7.32M6.21M5.90M2.76M1.11M25.57M6.00M38.84M50.52M75.46M105.77M167.51M2.56M2.54M
Gross Profit6.92M6.99M21.15M22.47M15.58M689.00K-25.26M-6.00M6.83M32.17M18.44M9.43M-167.51M-2.56M4.96M
Gross Margin100.00%48.84%77.30%79.19%100.00%38.21%-8122.83%-100.00%100.00%100.00%100.00%--66.09%
Operating Expense19.03M10.14M11.43M11.36M24.94M25.51M7.31M32.02M49.65M63.47M97.43M138.58M46.54M276.74M378.03M
Operating Income-12.11M-3.15M9.71M11.11M-9.36M-24.82M-32.58M-38.02M-42.82M-31.30M-78.99M-129.14M-214.05M-279.30M-373.07M
Operating Margin-175.11%-22.04%35.50%39.15%-60.10%-1376.43%-10474.28%--627.02%-97.31%-428.45%-1368.91%---4974.27%
EBITDA-10.77M-3.42M10.42M11.84M-8.32M-23.95M-30.05M-32.54M-39.76M-30.66M-78.09M-127.52M-210.51M-235.86M-342.35M
EBITDA Margin-155.67%-23.92%38.08%41.75%-53.43%-1328.51%-9663.99%--582.15%-95.31%-423.53%-1351.70%---4564.68%
Net Income-11.99M-4.30M12.03M13.02M-15.75M-23.00M-30.70M-34.50M-41.59M-28.84M-78.88M-125.37M-182.39M-234.33M-345.91M
Net Income Margin-173.34%-30.06%43.98%45.89%-101.12%-1275.49%-9872.67%--609.09%-89.65%-427.85%-1328.95%---4612.13%
R&D12.30M10.46M12.30M11.77M15.15M19.83M25.57M23.63M38.84M50.52M75.46M105.77M167.51M210.39M300.94M
R&D as % of Total Revenue177.83%73.07%44.97%41.48%97.27%1099.72%8222.83%-568.82%157.07%409.30%1121.13%--4012.51%
Interest Expense91.00K93.00K64.00K00001.39M1.43M484.00K1.01M5.51M---
Interest Expense % of Total Revenue1.32%0.65%0.23%0.00%0.00%0.00%0.00%-21.00%1.50%5.48%58.43%---

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-63.30M54.49M87.42M63.95M67.49M46.12M122.43M147.70M189.19M572.01M754.15M964.80M798.14M981.67M
Total Liabilities-50.68M30.37M14.64M2.92M3.59M10.19M19.13M55.72M17.83M21.97M32.65M36.88M43.24M399.91M
Total Equity-12.62M24.12M72.78M61.03M63.90M35.93M103.30M91.98M171.35M550.03M721.50M927.92M754.90M581.76M
Cash-60.16M37.95M72.03M58.65M17.09M20.49M67.75M24.75M45.01M175.69M57.24M148.64M142.71M199.16M
Total Debt-1.67M----6.80M15.01M16.45M3.31M8.26M10.44M10.90M9.02M7.94M
Net Debt--58.50M-37.95M-72.03M-58.65M-17.09M-13.68M-52.74M-8.30M-41.69M-167.43M-46.81M-137.74M-133.70M-191.22M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-13.69M45.57M-3.32M266.00K-18.10M-19.57M-28.73M-34.72M-4.63M-48.12M-69.50M-98.43M-145.33M-181.39M-279.12M
Investing Cash Flow13.89M491.00K-11.47M-3.24M10.19M-47.84M24.29M-28.99M-66.29M-16.82M-246.77M-296.00M-117.17M165.00M218.00M
Financing Cash Flow2.00K--4.39M41.12M278.00K23.96M7.07M111.59M27.52M85.80M447.54M278.47M353.52M12.13M117.11M
Capital Expenditure290.00K526.00K156.00K1.53M551.00K279.00K315.00K507.00K1.24M2.64M2.05M2.89M5.62M3.08M799.00K
Free Cash Flow-13.98M45.05M-3.48M-1.26M-18.65M-19.85M-29.04M-35.23M-5.87M-50.76M-71.55M-101.32M-150.94M-184.46M-279.92M
Dividends Paid---0000--------
FCF to OCF102.12%98.85%104.70%-474.81%103.04%101.43%101.10%101.46%126.77%105.48%102.95%102.94%103.87%101.70%100.29%
Dividend Paid to FCF---0.00%0.00%0.00%0.00%--------

Earnings

Report DateDec 15, 2014Mar 12, 2015May 12, 2015Aug 10, 2015Nov 10, 2015Mar 8, 2016May 10, 2016Aug 3, 2016Nov 3, 2016Mar 8, 2017May 9, 2017Aug 3, 2017Nov 7, 2017Mar 7, 2018May 8, 2018Aug 7, 2018Nov 6, 2018Mar 6, 2019May 7, 2019Aug 6, 2019Nov 5, 2019Mar 9, 2020May 21, 2020Aug 5, 2020Nov 5, 2020Mar 1, 2021May 11, 2021Aug 11, 2021Nov 10, 2021Mar 1, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Mar 1, 2023May 9, 2023Aug 9, 2023Nov 8, 2023Feb 29, 2024May 9, 2024Aug 8, 2024Nov 12, 2024Feb 26, 2025May 12, 2025Aug 11, 2025Nov 3, 2025Feb 26, 2026May 7, 2026Aug 6, 2026Nov 2, 2026
EPS Estimate0.05-0.010.28-0.30-0.03-0.16-0.21-0.50-0.44-0.42-0.38-0.39-0.39-0.11-0.48-0.49-0.40-0.37-0.37-0.45-0.46-0.48-0.31-0.20-0.17-0.40-0.39-0.49-0.44-0.37-0.41-0.50-0.53-0.58-0.60-0.67-0.75-0.76-0.65-0.68-0.79-0.84-0.90-0.99-1.16-1.20-1.20-1.16-1.17
EPS Actual1.692.54-0.300.08-0.27-0.27-0.23-0.42-0.51-0.32-0.42-0.41-0.43-0.45-0.46-0.45-0.63-0.29-0.42-0.37-0.33-0.42-0.22-0.00-0.25-0.34-0.42-0.51-0.36-0.48-0.35-0.55-0.57-0.57-0.63-0.72-0.73-0.64-0.62-0.75-0.81-0.84-0.83-1.07-1.15-1.31-1.17-1.11-
Surprise3280.00%25500.00%-207.14%126.67%-800.00%-68.75%-9.52%16.00%-15.91%23.81%-10.53%-5.13%-10.26%-309.09%4.17%8.16%-57.50%21.62%-13.51%17.78%28.26%12.50%29.03%97.55%-47.06%15.00%-7.69%-4.08%18.18%-29.73%14.63%-10.00%-7.55%1.72%-5.00%-7.46%2.67%15.79%4.62%-10.29%-2.53%-0.10%7.78%-8.08%0.86%-9.17%2.50%4.31%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap3.61B
Enterprise Value2.62B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio-0.06
Price / Sales727.44
Price / Book3.04
EPS-4.81
Book Value12.84
Revenue (TTM)0
Gross Profit (TTM)-352.48M
EBITDA-439.19M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-43.62%
Return on Assets-28.02%
Shares Outstanding96.84M
Shares Float90.95M
Beta0.62
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 19 analystsTarget 74.31
  • Strong Buy
    14
  • Buy
    5

Ownership Breakdown

Institutions
107.33%
Insiders
0.11%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    10.82M11.17%
  • venBio Select Advisor LLC
    5.78M5.97%
  • BlackRock Inc
    5.64M5.82%
  • Driehaus Capital Management LLC
    4.49M4.64%
  • Polar Capital Holdings PLC
    4.41M4.55%
  • HHG PLC
    4.18M4.31%
  • Capital Research & Mgmt Co - Division 3
    2.36M2.44%
  • JPMorgan Chase & Co
    1.92M1.99%
  • State Street Corp
    1.72M1.78%
  • Two Sigma Investments LLC
    1.64M1.70%
  • Deerfield Management Co
    1.62M1.67%
  • Affinity Asset Advisors, LLC
    1.59M1.65%
  • Holocene Advisors, LP
    1.52M1.57%
  • Westfield Capital Management Company, L.P.
    1.51M1.56%
  • Wellington Management Company LLP
    1.43M1.47%

Top Fund Holders

  • American Funds SMALLCAP World A
    3.12M3.23%
  • Polar Capital Biotech S Inc
    2.72M2.81%
  • iShares Russell 2000 ETF
    2.50M2.58%
  • Strategic Advisers Fidelity US TtlStk
    1.97M2.03%
  • Polar Capital Healthcare Opports Inc
    1.69M1.75%